Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 301 to 315 of 1003 results for public health medicine & health

  1. Enlicitide decanoate for treating hyperlipidaemia in people at risk of an atherosclerotic cardiovascular disease event [ID6656]

    Awaiting development Reference number: GID-TA11871 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Atrasentan for treating primary IgA nephropathy [ID6558]

    Awaiting development Reference number: GID-TA11756 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Carfilzomib in combination for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID12176]

    Awaiting development Reference number: GID-TA11752 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Sibeprenlimab for treating IgA nephropathy [ID6604]

    Awaiting development Reference number: GID-TA11668 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208]

    Awaiting development Reference number: GID-TA11778 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Blarcamesine for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6679]

    Awaiting development Reference number: GID-TA11717 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over [TSID11865]

    Awaiting development Reference number: GID-TA11358 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide [TSID10046]

    Awaiting development Reference number: GID-TA11335 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Denosumab biosimilar for Giant cell-rich tumours of bone or Skeletal events in bone malignancies [TSID12150]

    Awaiting development Reference number: GID-TA11783 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Inclisiran for treating familial hypercholesterolaemia and elevated low density lipoprotein cholesterol in people 12 to 17 years [TSID12129]

    Awaiting development Reference number: GID-TA11698 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset [TSID10190]

    Awaiting development Reference number: GID-TA11283 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping [TSID10593]

    Awaiting development Reference number: GID-TA10957 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659]

    Awaiting development Reference number: GID-TA11111 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Leriglitazone for treating X-linked andrenoleukodystrophy [TSID9996]

    Awaiting development Reference number: GID-TA11393 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. CAEL-101 with standard care for untreated amyloid light chain amyloidosis [ID6210]

    Awaiting development Reference number: GID-TA11182 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development